- Home
- SQM vs RPRX Comparison
SQM vs RPRX Comparison
Compare SQM & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SQM | RPRX |
|---|---|---|
| Founded | 1968 | 1996 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9B | 22.0B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SQM | RPRX |
|---|---|---|
| Price | $72.70 | $57.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $68.80 | $51.40 |
| AVG Volume (30 Days) | 1.0M | ★ 3.5M |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | 0.74% | ★ 1.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.67 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | N/A | $38.63 |
| Revenue Next Year | $7.83 | $4.73 |
| P/E Ratio | ★ $39.64 | $86.22 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $35.37 | $34.63 |
| 52 Week High | $98.00 | $57.79 |
Technical Indicators
Market Signals| Indicator | SQM | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.65 | 63.95 |
| Support Level | $68.06 | $38.07 |
| Resistance Level | $76.88 | N/A |
| Average True Range (ATR) | 2.62 | 1.50 |
| MACD | -0.37 | 0.16 |
| Stochastic Oscillator | 24.30 | 99.55 |
Price Performance
Historical ComparisonAbout SQM Sociedad Quimica y Minera S.A.
Sociedad Quimica y Minera de Chile is a Chilean commodities producer with significant operations in lithium (primarily used in batteries for electric vehicles and energy storage systems), specialty and standard potassium fertilizers, iodine (primarily used in X-ray contrast media), and solar salts. The company extracts these materials through its high-quality salt brine deposits and caliche ore. SQM also sells lithium concentrate from a joint venture hard rock lithium project in Australia and expanding its lithium refining assets in China.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.